Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cancer testis antigen methylation/expression and response to pembrolizumab in advanced lung adenocarcinoma
2017-000689-30Phase 2Completed
- Sponsor
- Medical University of Vienna
- Start
- May 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of pembrolizumab in Non-small cell lung cancer adenocarcinoma (NSCLC), sponsored by Medical University of Vienna. Primary endpoint: Objective response rate. Started May 2018; status: completed.
02
Drugs
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on 2017-000689-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000689-30.